The nurse is providing care for a patient with recurrent lymphocytic leukemia who is receiving weekly treatment with Campath (alemtuzumab). Which of the following lab results would the nurse be expected to monitor prior to initiating therapy? Select all that apply.
A) Prothrombin time (PTT)
B) Urine-specific gravity
C) White blood cell count (WBC)
D) Platelet count
E) CD-8 count
F) Red blood cell count (RBC)

Question

Quizplus · Accepted Answer

Alemtuzumab is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia. It targets CD52, a protein found on the surface of immune cells. Before initiating therapy with alemtuzumab, it is important to monitor blood counts to assess the patient's baseline status and potential risks for complications. Monitoring the White blood cell count (WBC) is crucial due to the drug's immunosuppressive effects, which can lead to leukopenia. The Platelet count is important to evaluate because thrombocytopenia is a potential side effect, increasing the risk of bleeding. The Red blood cell count (RBC) is also essential to monitor as anemia can be a complication of both the disease and its treatment.

The Nurse Is Providing Care for a Patient with Recurrent